Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: FAXDC2

Gene summary for FAXDC2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

FAXDC2

Gene ID

10826

Gene namefatty acid hydroxylase domain containing 2
Gene AliasC5orf4
Cytomap5q33.2
Gene Typeprotein-coding
GO ID

GO:0001932

UniProtAcc

Q96IV6


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
10826FAXDC2Dong_P3HumanProstateTumor8.96e-061.21e-010.0278
10826FAXDC2GSM5353221_PA_PB2A_Pool_1_3_S25_L001HumanProstateTumor1.50e-085.04e-010.1633
10826FAXDC2GSM5353222_PA_PB2B_Pool_1_3_S52_L002HumanProstateTumor4.19e-156.33e-010.1608
10826FAXDC2GSM5353223_PA_PB2B_Pool_2_S26_L001HumanProstateTumor7.25e-095.64e-010.1604
10826FAXDC2GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002HumanProstateTumor2.76e-044.02e-010.1602
10826FAXDC2GSM5353236_PA_PR5251_T1_S7_L001HumanProstateTumor5.17e-034.98e-010.1608
10826FAXDC2GSM5353237_PA_PR5251_T2_S8_L001HumanProstateTumor2.32e-025.02e-010.1622
10826FAXDC2GSM5353247_PA_PR5269_3_S27_L002HumanProstateTumor2.39e-026.22e-010.1532
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:003009919ProstateTumormyeloid cell differentiation120/3246381/187236.96e-125.62e-10120
GO:004563719ProstateTumorregulation of myeloid cell differentiation67/3246210/187231.71e-074.25e-0667
GO:190370617ProstateTumorregulation of hemopoiesis103/3246367/187231.78e-074.38e-06103
GO:004563915ProstateTumorpositive regulation of myeloid cell differentiation35/3246103/187233.29e-053.88e-0435
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
FAXDC2SNVMissense_Mutationnovelc.884N>Gp.His295Argp.H295RQ96IV6protein_codingtolerated(1)benign(0)TCGA-AO-A128-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinSD
FAXDC2insertionNonsense_Mutationnovelc.298_299insAAGTGGGTCCCACTGTTCCCTGAGTCTGGCTCGCCTTTTCCp.Val100GlufsTer8p.V100Efs*8Q96IV6protein_codingTCGA-A7-A0CE-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapyadriamycinSD
FAXDC2insertionNonsense_Mutationnovelc.578_579insGTATTTTTAGTAGGACAGGTTTTCACCATGTTGGTCAGGCTGGp.His194TyrfsTer3p.H194Yfs*3Q96IV6protein_codingTCGA-A8-A07J-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapy5-fluorouracilCR
FAXDC2deletionFrame_Shift_Delnovelc.846delNp.Lys282AsnfsTer124p.K282Nfs*124Q96IV6protein_codingTCGA-D8-A27V-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
FAXDC2SNVMissense_Mutationnovelc.700N>Gp.Ile234Valp.I234VQ96IV6protein_codingtolerated(0.76)benign(0.001)TCGA-VS-A8EC-01Cervixcervical & endocervical cancerFemale<65III/IVChemotherapycarboplatinCR
FAXDC2SNVMissense_Mutationnovelc.527N>Tp.Ala176Valp.A176VQ96IV6protein_codingtolerated(0.37)benign(0.007)TCGA-AA-3811-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownPD
FAXDC2SNVMissense_Mutationrs748240055c.341G>Ap.Arg114Glnp.R114QQ96IV6protein_codingdeleterious(0.04)benign(0.087)TCGA-AG-A002-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
FAXDC2SNVMissense_Mutationrs763500956c.367N>Ap.Val123Metp.V123MQ96IV6protein_codingdeleterious(0.04)possibly_damaging(0.749)TCGA-A5-A0G1-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
FAXDC2SNVMissense_Mutationnovelc.403G>Ap.Val135Ilep.V135IQ96IV6protein_codingdeleterious(0.04)benign(0.115)TCGA-A5-A1OF-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
FAXDC2SNVMissense_Mutationrs755057180c.643N>Ap.Val215Metp.V215MQ96IV6protein_codingdeleterious(0)benign(0.42)TCGA-A5-A2K5-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1